Abstract
One of the known risk factors for developing Alzheimer disease (AD) is hyperhomocysteinemia. The latter may result from mutations of the genes coding for three key enzymes involved in homocysteine metabolism (methylenetetrahydrofolate reductase [MTHFR], methionine synthase [MS], and cystathionine beta-synthase [CBS]). Although MTHFR and MS polymorphisms have been shown to be positively associated with AD in some populations, the relationship of the CBS gene with AD remains undefined. In order to evaluate whether AD is associated with CBS gene changes leading to decreased CBS activity and homocysteine accumulation, we genotyped the CBS 844ins68 mutation and VNTR polymorphisms of the CBS gene in 206 AD patients and 186 age-matched controls. A slight increase in both 844ins68 mutation and VNTR allele 19 frequencies was detected in the whole AD patient group, compared with controls. The division of AD patients and controls into three age-at-onset / age dependent subgroups ( < 65 years, 65-74 years, ≥ 75 years) revealed that the 844ins68 mutation and VNTR allele 19 are independent risk factors for AD development in subjects aged 75 years or more.
Keywords: alzheimer disease, cbs, 31 bp vntr, 844ins68 mutation, risk factors, age-at-onset/age
Current Alzheimer Research
Title: Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease
Volume: 1 Issue: 2
Author(s): Katrin Beyer, Jose I. Lao, Cristina Carrato, Ana Rodriguez-Vila, Pilar Latorre, Maria Mataro, Maria A. Llopis, Jose L. Mate and Aurelio Ariza
Affiliation:
Keywords: alzheimer disease, cbs, 31 bp vntr, 844ins68 mutation, risk factors, age-at-onset/age
Abstract: One of the known risk factors for developing Alzheimer disease (AD) is hyperhomocysteinemia. The latter may result from mutations of the genes coding for three key enzymes involved in homocysteine metabolism (methylenetetrahydrofolate reductase [MTHFR], methionine synthase [MS], and cystathionine beta-synthase [CBS]). Although MTHFR and MS polymorphisms have been shown to be positively associated with AD in some populations, the relationship of the CBS gene with AD remains undefined. In order to evaluate whether AD is associated with CBS gene changes leading to decreased CBS activity and homocysteine accumulation, we genotyped the CBS 844ins68 mutation and VNTR polymorphisms of the CBS gene in 206 AD patients and 186 age-matched controls. A slight increase in both 844ins68 mutation and VNTR allele 19 frequencies was detected in the whole AD patient group, compared with controls. The division of AD patients and controls into three age-at-onset / age dependent subgroups ( < 65 years, 65-74 years, ≥ 75 years) revealed that the 844ins68 mutation and VNTR allele 19 are independent risk factors for AD development in subjects aged 75 years or more.
Export Options
About this article
Cite this article as:
Beyer Katrin, Lao I. Jose, Carrato Cristina, Rodriguez-Vila Ana, Latorre Pilar, Mataro Maria, Llopis A. Maria, Mate L. Jose and Ariza Aurelio, Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease, Current Alzheimer Research 2004; 1 (2) . https://dx.doi.org/10.2174/1567205043332243
DOI https://dx.doi.org/10.2174/1567205043332243 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Therapeutic Potential of Rutin for Diabetes: An Update
Mini-Reviews in Medicinal Chemistry Current Concepts and Perspectives on Connexin43: A Mini Review
Current Protein & Peptide Science GRK2 Inhibition in Heart Failure: Something Old, Something New
Current Pharmaceutical Design Anti-Inflammatory Drugs and Prediction of New Structures by Comparative Analysis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Gene Expression Profiling Analysis to Identify Key Genes and Underlying Mechanisms in Meniscus of Osteoarthritis Patients
Combinatorial Chemistry & High Throughput Screening Antivitamin K Drugs in Stroke Prevention
Current Vascular Pharmacology Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Anti-platelet Drug-loaded Targeted Technologies for the Effective Treatment of Atherothrombosis
Current Drug Targets Insulin Resistance as a Therapeutic Target for Improved Endothelial Function:Metformin
Current Drug Targets - Cardiovascular & Hematological Disorders Medicinal Chemistry Approaches for Glucokinase Activation to Treat Type 2 Diabetes
Current Medicinal Chemistry HIV Infection and Myocardial Infarction
Current HIV Research Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets Lipid Lowering Drugs and Gallstones: A Therapeutic Option?
Current Pharmaceutical Design GRK2 and Beta-Arrestins in Cardiovascular Disease: Established and Emerging Possibilities for Therapeutic Targeting
Current Molecular Pharmacology Cardiovascular Disease Risk and Hormone Replacement Therapy (HRT): A Review Based on Randomised, Controlled Studies in Postmenopausal Women
Current Medicinal Chemistry Atrial Tachycardias Arising from the Atrial Appendages and Aortic Sinus of Valsalva
Current Cardiology Reviews Are Antipsychotics Useful in the Treatment of Anorexia Nervosa? A Review of the Literature
Current Psychopharmacology Pulmonary Complications After Congenital Heart Surgery
Current Respiratory Medicine Reviews Health Care Discovery, Novo Nordisk A/S, DK-2880 Bagsværd, Denmark
Current Pharmaceutical Biotechnology Editorial: New Insights into a Classical Pathway: Key Roles of the Mevalonate Cascade in Different Diseases (Part II)
Current Molecular Pharmacology